doxorubicin

Summary

Summary: Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.

Top Publications

  1. ncbi Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
    D J Slamon
    Division of Hematology and Oncology, UCLA School of Medicine, Los Angeles, Calif 90095 1678, USA
    N Engl J Med 344:783-92. 2001
  2. ncbi Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies
    Yanti Octavia
    Dept of Cardiology, Maastricht University Medical Centre, Cardiovascular Research Institute Maastricht, P Delbeyeplein 25, Maastricht, The Netherlands
    J Mol Cell Cardiol 52:1213-25. 2012
  3. ncbi CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group
    Michael Pfreundschuh
    University Clinic of Saarland, Homburg, Germany
    Lancet Oncol 7:379-91. 2006
  4. ncbi A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin
    D A Gewirtz
    Department of Pharmacology Toxicology, and Medical College of Virginia, Virginia Commonwealth University, Richmond 23298, USA
    Biochem Pharmacol 57:727-41. 1999
  5. ncbi Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone
    Tina Marie Green
    Department of Pathology, Odense University Hospital, J B Winsløws Vej 15, DK 5000 Odense C, Denmark
    J Clin Oncol 30:3460-7. 2012
  6. pmc Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone
    Nathalie A Johnson
    British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    J Clin Oncol 30:3452-9. 2012
  7. ncbi MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells
    Francesca Fornari
    Centro di Ricerca Biomedica Applicata e Dipartimento di Medicina Interna, Policlinico S Orsola Malpighi e Università di Bologna, Bologna, Italy
    Cancer Res 70:5184-93. 2010
  8. ncbi Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer
    Kenneth R Hess
    Department of Biostatistics and Applied Mathematics, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Clin Oncol 24:4236-44. 2006
  9. ncbi Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer
    Stan B Kaye
    The Royal Marsden National Health Service Foundation Trust and The Institute of Cancer Research, Sycamore House, Downs Rd, Sutton, Surrey SM2 5PT, UK
    J Clin Oncol 30:372-9. 2012
  10. ncbi Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial
    Josep M Llovet
    Liver Unit, Digestive Disease Institute, Hospital Clinic, University of Barcelona, Barcelona, Spain
    Lancet 359:1734-9. 2002

Detail Information

Publications374 found, 100 shown here

  1. ncbi Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
    D J Slamon
    Division of Hematology and Oncology, UCLA School of Medicine, Los Angeles, Calif 90095 1678, USA
    N Engl J Med 344:783-92. 2001
    ..The HER2 gene, which encodes the growth factor receptor HER2, is amplified and HER2 is overexpressed in 25 to 30 percent of breast cancers, increasing the aggressiveness of the tumor...
  2. ncbi Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies
    Yanti Octavia
    Dept of Cardiology, Maastricht University Medical Centre, Cardiovascular Research Institute Maastricht, P Delbeyeplein 25, Maastricht, The Netherlands
    J Mol Cell Cardiol 52:1213-25. 2012
    ..It has been calculated that approximately 10% of patients treated with doxorubicin or its derivatives will develop cardiac complications up to 10 years after the cessation of chemotherapy...
  3. ncbi CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group
    Michael Pfreundschuh
    University Clinic of Saarland, Homburg, Germany
    Lancet Oncol 7:379-91. 2006
    The role of rituximab in combination with different CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-like chemotherapy regimens in young patients with good-prognosis diffuse large-B-cell lymphoma remains to be defined...
  4. ncbi A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin
    D A Gewirtz
    Department of Pharmacology Toxicology, and Medical College of Virginia, Virginia Commonwealth University, Richmond 23298, USA
    Biochem Pharmacol 57:727-41. 1999
    The mechanisms responsible for the antiproliferative and cytotoxic effects of the anthracycline antibiotics doxorubicin (Adriamycin) and daunorubicin (daunomycin) have been the subject of considerable controversy...
  5. ncbi Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone
    Tina Marie Green
    Department of Pathology, Odense University Hospital, J B Winsløws Vej 15, DK 5000 Odense C, Denmark
    J Clin Oncol 30:3460-7. 2012
    ..DHLs are characterized by poor outcome. We tested whether DLBCLs with high expression of MYC protein and BCL2 protein share the clinical features and poor prognosis of DHLs...
  6. pmc Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone
    Nathalie A Johnson
    British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    J Clin Oncol 30:3452-9. 2012
    ..Diffuse large B-cell lymphoma (DLBCL) is curable in 60% of patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)...
  7. ncbi MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells
    Francesca Fornari
    Centro di Ricerca Biomedica Applicata e Dipartimento di Medicina Interna, Policlinico S Orsola Malpighi e Università di Bologna, Bologna, Italy
    Cancer Res 70:5184-93. 2010
    ..cycle arrest, reduced invasive capability, enhanced susceptibility to hypoxia, and increased sensitivity to doxorubicin-induced apoptosis...
  8. ncbi Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer
    Kenneth R Hess
    Department of Biostatistics and Applied Mathematics, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Clin Oncol 24:4236-44. 2006
    We developed a multigene predictor of pathologic complete response (pCR) to preoperative weekly paclitaxel and fluorouracil-doxorubicin-cyclophosphamide (T/FAC) chemotherapy and assessed its predictive accuracy on independent cases.
  9. ncbi Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer
    Stan B Kaye
    The Royal Marsden National Health Service Foundation Trust and The Institute of Cancer Research, Sycamore House, Downs Rd, Sutton, Surrey SM2 5PT, UK
    J Clin Oncol 30:372-9. 2012
    ..We assessed the comparative efficacy and safety of olaparib and pegylated liposomal doxorubicin (PLD) in this patient population.
  10. ncbi Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial
    Josep M Llovet
    Liver Unit, Digestive Disease Institute, Hospital Clinic, University of Barcelona, Barcelona, Spain
    Lancet 359:1734-9. 2002
    ..There is no standard treatment for unresectable hepatocellular carcinoma. Arterial embolisation is widely used, but evidence of survival benefits is lacking...
  11. pmc Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy
    C Marcela Diaz-Montero
    Department of Surgery, Medical University of South Carolina, Hollings Cancer Center, Charleston, SC, USA
    Cancer Immunol Immunother 58:49-59. 2009
    ..In 17 early stage breast cancer patients receiving doxorubicin-cyclophosphamide chemotherapy every 14 days (ddAC) blood was collected on day 1 of each cycle...
  12. ncbi Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer
    M E R O'Brien
    Kent Cancer Center, Maidstone, UK
    Ann Oncol 15:440-9. 2004
    ..was designed to demonstrate that efficacy [progression-free survival (PFS)] of CAELYX [pegylated liposomal doxorubicin HCl (PLD)] is non-inferior to doxorubicin with significantly less cardiotoxicity in first-line treatment of ..
  13. ncbi Identification of the molecular basis of doxorubicin-induced cardiotoxicity
    Sui Zhang
    Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Nat Med 18:1639-42. 2012
    b>Doxorubicin is believed to cause dose-dependent cardiotoxicity through redox cycling and the generation of reactive oxygen species (ROS)...
  14. pmc p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer
    James G Jackson
    Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Cell 21:793-806. 2012
    ..b>Doxorubicin-treated p53 mutant tumors failed to arrest proliferation, leading to abnormal mitoses and cell death, whereas ..
  15. ncbi Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study
    H von der Maase
    Aarhus University Hospital, Denmark
    J Clin Oncol 18:3068-77. 2000
    Gemcitabine plus cisplatin (GC) and methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) were compared in patients with locally advanced or metastatic transitional-cell carcinoma (TCC) of the urothelium.
  16. ncbi Drug combinations with quercetin: doxorubicin plus quercetin in human breast cancer cells
    Davide Staedler
    Centre Hospitalier Universitaire Vaudois CHUV and University of Lausanne UNIL, Lausanne, Switzerland
    Cancer Chemother Pharmacol 68:1161-72. 2011
    b>Doxorubicin is a first-line chemotherapeutic for breast cancer; however, it is associated with severe side effects to non-tumoral tissues...
  17. ncbi Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line
    S P Cole
    Cancer Research Laboratories, Queen s University, Kingston, Ontario, Canada
    Science 258:1650-4. 1992
    The doxorubicin-selected lung cancer cell line H69AR is resistant to many chemotherapeutic agents...
  18. pmc Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line
    Huan Meng
    Division of NanoMedicine, Department of Medicine, University of California, Los Angeles, California 90095, USA
    ACS Nano 4:4539-50. 2010
    ..mesoporous silica nanoparticles (MSNP) can be functionalized to effectively deliver a chemotherapeutic agent doxorubicin (Dox) as well as Pgp siRNA to a drug-resistant cancer cell line (KB-V1 cells) to accomplish cell killing in an ..
  19. ncbi Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27
    Priya Rastogi
    University of Pittsburgh Cancer Institute Magee Womens Hospital, 300 Halket St, Room 3524, Pittsburgh, PA 15213, USA
    J Clin Oncol 26:778-85. 2008
    ..Adjuvant Breast and Bowel Project (NSABP) Protocol B-18 was designed to determine whether four cycles of doxorubicin and cyclophosphamide (AC) administered preoperatively improved breast cancer disease-free survival (DFS) and ..
  20. ncbi Functional graphene oxide as a nanocarrier for controlled loading and targeted delivery of mixed anticancer drugs
    Liming Zhang
    Suzhou Institute of Nano tech and Nano bionics, Chinese Academy of Sciences, 398 Ruoshui Road, Dushu Lake Higher Education Town, Suzhou Industrial Park, Suzhou 215125, P R China
    Small 6:537-44. 2010
    ..Furthermore, controlled loading of two anticancer drugs, doxorubicin (DOX) and camptothecin (CPT), onto the FA-conjugated NGO (FA-NGO) via pi-pi stacking and hydrophobic ..
  21. ncbi Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18
    B Fisher
    Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Shadyside Hospital, PA, USA
    J Clin Oncol 15:2483-93. 1997
    To determine whether preoperative doxorubicin and cyclophosphamide (AC) permits more lumpectomies to be performed and decreases the incidence of positive nodes in women with primary breast cancer.
  22. pmc The CO/HO system reverses inhibition of mitochondrial biogenesis and prevents murine doxorubicin cardiomyopathy
    Hagir B Suliman
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Clin Invest 117:3730-41. 2007
    The clinical utility of anthracycline anticancer agents, especially doxorubicin, is limited by a progressive toxic cardiomyopathy linked to mitochondrial damage and cardiomyocyte apoptosis...
  23. ncbi Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial
    Jean Luc Harousseau
    Centre Rene Gauducheau, Nantes St Herblain, France
    J Clin Oncol 28:4621-9. 2010
    To compare efficacy and safety of bortezomib plus dexamethasone and vincristine plus doxorubicin plus dexamethasone (VAD) as induction before stem-cell transplantation in previously untreated myeloma.
  24. ncbi ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma
    Natasha Y Frank
    Department of Genetics, Children s Hospital Boston, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Res 65:4320-33. 2005
    ..We found that ABCB5 blockade significantly reversed resistance of G3361 melanoma cells to doxorubicin, an agent to which clinical melanomas have been found refractory, resulting in a 43% reduction in the LD50 from ..
  25. ncbi Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
    Michael Pfreundschuh
    Internal Medicine, Saarland University Medical School, Saarland University, Homburg, Germany
    Lancet Oncol 9:105-16. 2008
    Cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) is used to treat patients with non-Hodgkin lymphoma...
  26. ncbi CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
    Bertrand Coiffier
    Hospices Civils de Lyon and the Université Claude Bernard, Lyons, France
    N Engl J Med 346:235-42. 2002
    The standard treatment for patients with diffuse large-B-cell lymphoma is cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)...
  27. ncbi Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease
    David J Straus
    Memorial Sloan Kettering Cancer Center, SR 441B Box 406, 1275 York Ave, New York, NY 10021, USA
    Blood 104:3483-9. 2004
    ..stages (CSs) IA, IB, IIA, IIB, and IIIA without bulk disease were prospectively randomized to 6 cycles of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) alone or 6 cycles of ABVD followed by radiation therapy (RT) (3600 ..
  28. ncbi MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells
    Francesca Fornari
    Dipartimento di Medicina Clinica e CRBA, Policlinico S Orsola Malpighi, Bologna, Italy
    Cancer Res 69:5761-7. 2009
    ..the role of miR-122 and cyclin G1 expression in hepatocarcinogenesis and in response to treatment with doxorubicin and their relevance on survival and time to recurrence (TTR) of HCC patients...
  29. ncbi Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte
    P Feugier
    Hematology Department, Centre Hospitalier Universitaire de Brabois, 54500 Vandoeuvre les Nancy, France
    J Clin Oncol 23:4117-26. 2005
    ..outcome of patients included in the Lymphome Non Hodgkinien study 98-5 (LNH98-5) comparing cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) to rituximab plus CHOP (R-CHOP) in elderly patients with diffuse large B-..
  30. ncbi Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin
    Olga Kovalchuk
    Department of Biological Sciences, University of Lethbridge, Lethbridge, Alberta, Canada T1K 3M4
    Mol Cancer Ther 7:2152-9. 2008
    ..study, we investigated the role of miRNA in the resistance of human MCF-7 breast adenocarcinoma cells to doxorubicin (DOX)...
  31. pmc Phosphorylation of FOXO3a on Ser-7 by p38 promotes its nuclear localization in response to doxorubicin
    Ka Kei Ho
    Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, London W12 0NN, United Kingdom
    J Biol Chem 287:1545-55. 2012
    ..b>Doxorubicin treatment of MCF-7 breast carcinoma cells results in FOXO3a nuclear relocation and the induction of the stress-..
  32. ncbi Doxorubicin: the good, the bad and the ugly effect
    Cristina Carvalho
    Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal
    Curr Med Chem 16:3267-85. 2009
    The anthracycline doxorubicin (DOX) is widely used in chemotherapy due to its efficacy in fighting a wide range of cancers such as carcinomas, sarcomas and hematological cancers...
  33. ncbi Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98
    Sherene Loi
    Breast Cancer Translational Research Laboratory BCTL J C Heuson, Institut Jules Bordet, Blvd de Waterloo, 125, 1000 Brussels, Belgium
    J Clin Oncol 31:860-7. 2013
    ..We hypothesized that increased lymphocytic infiltration would be associated with good prognosis and benefit from immunogenic CT-in this case, anthracycline-only CT-in selected BC subtypes...
  34. pmc Targeting JNK-interacting-protein-1 (JIP1) sensitises osteosarcoma to doxorubicin
    Jantine Posthumadeboer
    Department of Orthopaedic Surgery, VU University Medical Center, Amsterdam, The Netherlands
    Oncotarget 3:1169-81. 2012
    ..a loss-of-function siRNA screen of the human kinome in SaOS-2 cells to identify critical survival kinases after doxorubicin treatment...
  35. pmc The kinetics of blood brain barrier permeability and targeted doxorubicin delivery into brain induced by focused ultrasound
    Juyoung Park
    Department of Radiology, Brigham and Women s Hospital and Harvard Medical School, 221 Longwood Ave Boston, MA 02115, USA
    J Control Release 162:134-42. 2012
    ..permeability using dynamic contrast-enhanced MRI (DCE-MRI) and the resulting payload of the chemotherapy agent, doxorubicin (DOX)...
  36. ncbi Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems
    Oktay Tacar
    School of Biomedical and Health Sciences, Victoria University, St Albans, Australia
    J Pharm Pharmacol 65:157-70. 2013
    The frontline drug doxorubicin has been used for treating cancer for over 30 years...
  37. pmc Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment
    Maria Volkova
    Section of Cardiovascular Medicine, Yale University School of Medicine, USA
    Curr Cardiol Rev 7:214-20. 2011
    Anthracyclines, such as doxorubicin and idarubicin, remain an important class of chemotherapeutic agents...
  38. ncbi Focused ultrasound and interleukin-4 receptor-targeted liposomal doxorubicin for enhanced targeted drug delivery and antitumor effect in glioblastoma multiforme
    Feng Yi Yang
    Department of Biomedical Imaging and Radiological Sciences, National Yang Ming University, Taipei, Taiwan
    J Control Release 160:652-8. 2012
    ..that pulsed HIFU and human atherosclerotic plaque-specific peptide-1 (AP-1)-conjugated liposomes containing doxorubicin (AP-1 Lipo-Dox) act synergistically in an experimental brain tumor model...
  39. pmc Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide
    J Bray
    Northern Institute for Cancer Research, Medical School, Newcastle University, Newcastle upon Tyne, UK
    Br J Cancer 102:1003-9. 2010
    b>Doxorubicin and cyclophosphamide (AC) therapy is an effective treatment for early-stage breast cancer. Doxorubicin is a substrate for ABCB1 and SLC22A16 transporters...
  40. pmc RGD peptide-mediated chitosan-based polymeric micelles targeting delivery for integrin-overexpressing tumor cells
    Li Li Cai
    College of Pharmaceutical Science, Zhejiang University, Hangzhou, People s Republic of China
    Int J Nanomedicine 6:3499-508. 2011
    ..Thus, the targeting of RGD-modified micelles to tumor vasculature is a promising strategy for tumor-targeting treatment...
  41. ncbi Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death
    Lonnie P Swift
    Department of Biochemistry, La Trobe University, Victoria, Australia
    Cancer Res 66:4863-71. 2006
    b>Doxorubicin (Adriamycin) is one of the most commonly used chemotherapeutic drugs and exhibits a wide spectrum of activity against solid tumors, lymphomas, and leukemias...
  42. pmc Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway
    Takahiro Horie
    Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawaharacho, Sakyo ku, Kyoto 606 8507, Japan
    Cardiovasc Res 87:656-64. 2010
    ..CHF) was reported when the anti-ErbB2 antibody trastuzumab was used in combination with the chemotherapy drug doxorubicin (Dox). The aim of the present study was to investigate the role(s) of miRNAs in acute Dox-induced cardiotoxicity...
  43. ncbi p53DINP1, a p53-inducible gene, regulates p53-dependent apoptosis
    S Okamura
    Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, University of Tokyo, 4 6 1 Shirokanedai, Minato ku, 108 8639, Tokyo, Japan
    Mol Cell 8:85-94. 2001
    ..Our results suggest that p53DINP1 may regulate p53-dependent apoptosis through phosphorylation of p53 at Ser46, serving as a cofactor for the putative p53-Ser46 kinase...
  44. ncbi Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems
    Norased Nasongkla
    Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, Texas 75390, USA
    Nano Lett 6:2427-30. 2006
    ..b>Doxorubicin and a cluster of superparamagnetic iron oxide (SPIO) nanoparticles were loaded successfully inside the micelle ..
  45. ncbi The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
    Laurie H Sehn
    Division of Medical Oncology, British Columbia Cancer Agency and the University of British Columbia, Vancouver, Canada
    Blood 109:1857-61. 2007
    ..In the era of R-CHOP treatment, the R-IPI is a clinically useful prognostic index that may help guide treatment planning and interpretation of clinical trials...
  46. ncbi Progressive adriamycin nephropathy in mice: sequence of histologic and immunohistochemical events
    Y Wang
    Department of Renal Medicine, University of Sydney at Westmead Hospital, Westmead, Australia
    Kidney Int 58:1797-804. 2000
    ..Herein, we describe a stable and reproducible murine model of chronic proteinuria induced by ADR...
  47. pmc Doxorubicin cardiomyopathy
    Kanu Chatterjee
    Department of Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa 52242 1081, USA kanu chatterjee uiowa edu
    Cardiology 115:155-62. 2010
    Established doxorubicin cardiomyopathy is a lethal disease. When congestive heart failure develops, mortality is approximately 50%...
  48. ncbi Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas
    Maria A Kouvaraki
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 22:4762-71. 2004
    ..studied 84 patients with locally advanced or metastatic PEC who had been treated with fluorouracil, doxorubicin, and streptozocin (FAS) to determine the objective response rate, duration of progression-free survival (PFS), ..
  49. ncbi Supramolecular chemistry on water-soluble carbon nanotubes for drug loading and delivery
    Zhuang Liu
    Department of Chemistry, Stanford University, Stanford, California 94305, USA
    ACS Nano 1:50-6. 2007
    ..these routes allow for surprisingly high degrees of pi-stacking of aromatic molecules, including a cancer drug (doxorubicin) with ultrahigh loading capacity, a widely used fluorescence molecule (fluorescein), and combinations of ..
  50. ncbi Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management
    Genzou Takemura
    Second Department of Internal Medicine, Gifu University School of Medicine, Gifu, Japan
    Prog Cardiovasc Dis 49:330-52. 2007
    First isolated in the early 1960s, doxorubicin (DOX) remains among the most effective anticancer drug ever developed...
  51. ncbi Active repression of antiapoptotic gene expression by RelA(p65) NF-kappa B
    Kirsteen J Campbell
    School of Life Sciences, Division of Gene Regulation and Expression, MSI WTB complex, Dow Street, University of Dundee, Dundee DD1 5EH, Scotland, United Kingdom
    Mol Cell 13:853-65. 2004
    ..B induced by cytotoxic stimuli, such as ultraviolet light (UV-C) and the chemotherapeutic drugs daunorubicin/doxorubicin, is functionally distinct to that seen with the inflammatory cytokine TNF and is an active repressor of ..
  52. ncbi Adriamycin nephropathy: a model of focal segmental glomerulosclerosis
    Vincent W S Lee
    Centre for Transplant and Renal Research, Westmead Millennium Institute, University of Sydney at Westmead Hospital, Sydney, New South Wales, Australia
    Nephrology (Carlton) 16:30-8. 2011
    ..This review will outline the pharmacological behaviour of Adriamycin, and describe in detail the model of AN, including its key structural characteristics, genetic susceptibility and pathogenesis...
  53. ncbi Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy
    A A Gabizon
    Sharet Institute of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel
    Cancer Invest 19:424-36. 2001
    Pegylated liposomal doxorubicin (Doxil, Caelyx) is a formulation of doxorubicin in poly(ethylene glycol)-coated (stealth) liposomes with a prolonged circulation time and unique toxicity profile...
  54. ncbi Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials
    Sandra M Swain
    National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20889, USA
    Cancer 97:2869-79. 2003
    b>Doxorubicin is a highly effective and widely used cytotoxic agent with application that is limited by cardiotoxicity related to the cumulative dose of the drug...
  55. pmc Biodegradable luminescent porous silicon nanoparticles for in vivo applications
    Ji Ho Park
    Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, California 92093, USA
    Nat Mater 8:331-6. 2009
    ..These results demonstrate a new type of multifunctional nanostructure with a low-toxicity degradation pathway for in vivo applications...
  56. ncbi Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the Sirt1 pathway
    Elizabeth D Brookins Danz
    Center for Cardiovascular Sciences, Albany Medical College, Albany, NY 12208, USA
    Free Radic Biol Med 46:1589-97. 2009
    b>Doxorubicin (DOX) is one of the most effective chemotherapeutic drugs; however, its incidence of cardiotoxicity compromises its therapeutic index...
  57. ncbi Targeted delivery of doxorubicin to the rat brain at therapeutic levels using MRI-guided focused ultrasound
    Lisa H Treat
    Department of Radiology, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Int J Cancer 121:901-7. 2007
    ..Although doxorubicin (DOX) has been named as a strong candidate for chemotherapy of the central nervous system (CNS), the BBB often ..
  58. ncbi Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. intermediacy of H(2)O(2)- and p53-dependent pathways
    Suwei Wang
    Department of Biophysics and Free Radical Research Center, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, USA
    J Biol Chem 279:25535-43. 2004
    b>Doxorubicin (DOX), a widely used chemotherapeutic agent, exhibits cardiotoxicity as an adverse side effect in cancer patients...
  59. ncbi Selenium sensitizes MCF-7 breast cancer cells to doxorubicin-induced apoptosis through modulation of phospho-Akt and its downstream substrates
    Song Li
    Department of Cancer Chemoprevention, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Mol Cancer Ther 6:1031-8. 2007
    b>Doxorubicin is an effective drug against breast cancer. However, the favorable therapeutic response to doxorubicin is often associated with severe toxicity...
  60. ncbi Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse
    Eric Pujade-Lauraine
    University Paris Descartes, Assistance Publique Hopitaux de Paris, Hopital Hotel Dieu, Paris, France
    J Clin Oncol 28:3323-9. 2010
    ..III noninferiority trial was designed to test the efficacy and safety of the combination of pegylated liposomal doxorubicin (PLD) with carboplatin (CD) compared with standard carboplatin and paclitaxel (CP) in patients with platinum-..
  61. ncbi Pharmacological induction of Hsp70 protects apoptosis-prone cells from doxorubicin: comparison with caspase-inhibitor- and cycle-arrest-mediated cytoprotection
    Z N Demidenko
    Brander Cancer Research Institute, New York Medical College, Valhalla, NY, USA
    Cell Death Differ 13:1434-41. 2006
    ..Here we investigated effects of GA and 17-AAG in apoptosis-prone cells such as HL60 and U937. In these cells, doxorubicin (DOX) caused rapid apoptosis, whereas GA-induced heat-shock protein-70 (Hsp70) (a potent inhibitor of apoptosis)..
  62. ncbi Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer
    Hans von der Maase
    Department of Oncology, Aarhus University Hospital, DK 8000 Aarhus C, Denmark
    J Clin Oncol 23:4602-8. 2005
    To compare long-term survival in patients with locally advanced or metastatic transitional cell carcinoma (TCC) of the urothelium treated with gemcitabine/cisplatin (GC) or methotrexate/vinblastine/doxorubicin/cisplatin (MVAC).
  63. pmc A derivate of the antibiotic doxorubicin is a selective inhibitor of dengue and yellow fever virus replication in vitro
    Suzanne J F Kaptein
    Rega Institute for Medical Research, Minderbroedersstraat 10, B 3000 Leuven, Belgium
    Antimicrob Agents Chemother 54:5269-80. 2010
    A doxorubicin derivate, SA-17, that carries a squaric acid amide ester moiety at the carbohydrate (α-l-daunosaminyl) group was identified as a selective inhibitor of in vitro dengue virus (DENV) serotype 2 replication (50% effective ..
  64. pmc Doxorubicin and daunorubicin induce processing and release of interleukin-1β through activation of the NLRP3 inflammasome
    Kristin A D Sauter
    Department of Cell and Developmental Biology, Oregon Health and Science University, Portland, USA
    Cancer Biol Ther 11:1008-16. 2011
    Anthracyclines including doxorubicin and daunorubicin are commonly used for the treatment of both hematologic and solid tumors. Dose related adverse effects often limit the effectiveness of anthracyclines in chemotherapy...
  65. pmc Exceptionally high payload of doxorubicin in hollow gold nanospheres for near-infrared light-triggered drug release
    Jian You
    Department of Experimental Diagnostic Imaging, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    ACS Nano 4:1033-41. 2010
    ..Significantly greater cell killing was observed when MDA-MB-231 cells incubated with DOX-loaded HAuNS were irradiated with NIR light, attributable to both HAuNS-mediated photothermal ablation and cytotoxicity of released free DOX...
  66. pmc Salinomycin sensitizes cancer cells to the effects of doxorubicin and etoposide treatment by increasing DNA damage and reducing p21 protein
    Ju Hwa Kim
    Research Institute, National Cancer Center, Ilsan gu, Goyang si, Gyeonggi Do, South Korea
    Br J Pharmacol 162:773-84. 2011
    Salinomycin (Sal) has recently been shown to inhibit various cancer stem cells. Here, we investigated whether Sal could sensitize cancer cells to the effects of doxorubicin (DOX) or etoposide (ETO).
  67. pmc Improved anti-tumor effect of liposomal doxorubicin after targeted blood-brain barrier disruption by MRI-guided focused ultrasound in rat glioma
    Lisa H Treat
    Harvard MIT Division of Health Sciences and Technology, Cambridge, MA, USA
    Ultrasound Med Biol 38:1716-25. 2012
    ..Here, we investigated the effect of FUS-enhanced delivery of doxorubicin on survival in rats with and 9L gliosarcoma cells inoculated in the brain...
  68. ncbi Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial
    Sandro Pignata
    Istituto Nazionale Tumori, Via Mariano Semmola, 80131 Napoli, Italy
    J Clin Oncol 29:3628-35. 2011
    ..Multicentre Italian Trials in Ovarian Cancer-2 (MITO-2), an academic multicenter phase III trial, tested whether carboplatin/pegylated liposomal doxorubicin (PLD) was more effective than standard chemotherapy.
  69. ncbi Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01
    Francesco D'Amore
    Dept Hematology, Aarhus University Hospital, DK 8000 Aarhus C, Denmark
    J Clin Oncol 30:3093-9. 2012
    ..This is the final report, with a 5-year median follow-up, of the NLG-T-01 study...
  70. pmc Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298
    Lili Bao
    Department of Pathology and Laboratory Medicine, Tulane University Health Sciences Center, New Orleans, LA 70112, USA
    Am J Pathol 180:2490-503. 2012
    ..We have developed doxorubicin-resistant and -sensitive metastatic human breast cancer cell lines (MDA-MB-231) to study the chemoresistant ..
  71. ncbi Tailor-made dual pH-sensitive polymer-doxorubicin nanoparticles for efficient anticancer drug delivery
    Jin Zhi Du
    CAS Key Laboratory of Soft Matter Chemistry, and Department of Polymer Science and Engineering, University of Science and Technology of China, Hefei, Anhui 230026, PR China
    J Am Chem Soc 133:17560-3. 2011
    ..0) further promotes doxorubicin release from the endocytosed drug carriers...
  72. pmc Effective photothermal chemotherapy using doxorubicin-loaded gold nanospheres that target EphB4 receptors in tumors
    Jian You
    College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, PR China
    Cancer Res 72:4777-86. 2012
    ..Here, we synthesized multifunctional doxorubicin (DOX)-loaded hollow gold nanospheres (DOX@HAuNS) that target EphB4, a member of the Eph family of receptor ..
  73. ncbi Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate
    Paul A Meyers
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 23:2004-11. 2005
    ..whether the addition of ifosfamide and/or muramyl tripeptide (MTP) encapsulated in liposomes to cisplatin, doxorubicin, and high-dose methotrexate (HDMTX) could improve the probability for event-free survival (EFS) in newly ..
  74. pmc A therapeutic dose of doxorubicin activates ubiquitin-proteasome system-mediated proteolysis by acting on both the ubiquitination apparatus and proteasome
    Jinbao Liu
    Department of Pathophysiology, Guangzhou Medical College, 195 W Dongfeng Rd, Guangzhou, Guangdong, China
    Am J Physiol Heart Circ Physiol 295:H2541-50. 2008
    ..It has been previously shown that doxorubicin (Dox) enhances the degradation of a UPS surrogate substrate in mouse hearts...
  75. pmc Mitochondrial superoxide mediates doxorubicin-induced keratinocyte apoptosis through oxidative modification of ERK and Bcl-2 ubiquitination
    Sudjit Luanpitpong
    Department of Pharmaceutical Sciences, West Virginia University, Morgantown, WV 26506, USA
    Biochem Pharmacol 83:1643-54. 2012
    ..The present study investigated the apoptotic effect of doxorubicin (DOX) on HaCaT keratinocytes and determined the underlying mechanisms...
  76. pmc Nilotinib counteracts P-glycoprotein-mediated multidrug resistance and synergizes the antitumoral effect of doxorubicin in soft tissue sarcomas
    Victor Hugo Villar
    Clinical and Translational Research Group, Department of Biology, Institut Universitari d Investigacions en Ciències de la Salut IUNICS, University of the Balearic Islands, Palma de Mallorca, Spain
    PLoS ONE 7:e37735. 2012
    The therapeutic effect of doxorubicin (DXR) in the treatment of soft tissue sarcomas (STS) is limited by its toxicity and the development of multidrug resistance (MDR), the latter mainly induced by high expression of efflux pumps (e.g...
  77. pmc Drug resistance in breast cancer cells: biophysical characterization of and doxorubicin interactions with membrane lipids
    Chiranjeevi Peetla
    Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195, United States
    Mol Pharm 7:2334-48. 2010
    ..In this study, we isolated lipids from doxorubicin-sensitive (MCF-7) and -resistant (MCF-7/ADR) breast cancer cells to characterize the biophysical properties of ..
  78. pmc Doxorubicin loaded iron oxide nanoparticles overcome multidrug resistance in cancer in vitro
    Forrest M Kievit
    Department of Materials Science and Engineering, University of Washington, Seattle, WA 98195, USA
    J Control Release 152:76-83. 2011
    ..b>Doxorubicin (DOX), an anthracycline antibiotic commonly used in cancer chemotherapy and substrate for ABC-mediated drug ..
  79. pmc Nox2 NADPH oxidase promotes pathologic cardiac remodeling associated with Doxorubicin chemotherapy
    YouYou Zhao
    Centre for Vision and Vascular Science, Queen s University Belfast, Belfast, United Kingdom
    Cancer Res 70:9287-97. 2010
    b>Doxorubicin is a highly effective cancer treatment whose use is severely limited by dose-dependent cardiotoxicity. It is well established that doxorubicin increases reactive oxygen species (ROS) production...
  80. pmc Targeted delivery of doxorubicin-utilizing chitosan nanoparticles surface-functionalized with anti-Her2 trastuzumab
    Parisa Yousefpour
    Department of Biotechnology, Faculty of Science, University of Tehran, Tehran, Iran
    Int J Nanomedicine 6:1977-90. 2011
    ..In this study, the monoclonal antibody, trastuzumab, was used as a targeting agent in nanoparticles carrying the antitumor drug, doxorubicin, specifically to its site of action.
  81. ncbi Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles
    Hai Wang
    CAS Key Laboratory for Biological Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology, Beijing 100190, China
    Biomaterials 32:8281-90. 2011
    ..More importantly, these NPs could co-deliver hydrophilic doxorubicin (DOX) and hydrophobic paclitaxel (TAX)...
  82. pmc Adiponectin ameliorates doxorubicin-induced cardiotoxicity through Akt protein-dependent mechanism
    Sonomi Maruyama
    Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya 466 8550, Japan
    J Biol Chem 286:32790-800. 2011
    Accumulating evidence shows that obesity is associated with doxorubicin cardiac toxicity in the heart, but the molecular mechanisms that contribute to this pathological response are not understood...
  83. ncbi Mechanisms and management of doxorubicin cardiotoxicity
    Y Shi
    Division of Cardiology, Heart and Stroke Richard Lewar Centre of Excellence, University Health Network, University of Toronto, Toronto General Hospital, Ontario, Canada
    Herz 36:296-305. 2011
    b>Doxorubicin is an effective anti-tumor agent with a cumulative dose-dependent cardiotoxicity...
  84. pmc Doxorubicin in combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast cancer in mouse models
    Abhik Bandyopadhyay
    Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, Texas, United States of America
    PLoS ONE 5:e10365. 2010
    ..TGFbeta is a potent inducer of EMT and has been shown to promote tumor progression in various breast cancer cell and animal models...
  85. pmc Cardiomyocyte death in doxorubicin-induced cardiotoxicity
    Yi Wei Zhang
    Riley Heart Research Center, Wells Center for Pediatric Research, Indiana University, School of Medicine, Indianapolis, IN 46202 5225, USA
    Arch Immunol Ther Exp (Warsz) 57:435-45. 2009
    b>Doxorubicin (DOX) is one of the most widely used and successful antitumor drugs, but its cumulative and dose-dependent cardiac toxicity has been a major concern of oncologists in cancer therapeutic practice for decades...
  86. pmc Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer
    Adel Tabchy
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1439, USA
    Clin Cancer Res 16:5351-61. 2010
    ..predictor (DLDA-30) of pathologic complete response (pCR) to preoperative weekly paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide (T/FAC) chemotherapy, and assessed if DLDA-30 also predicts increased sensitivity to FAC-..
  87. pmc Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model
    Marie Eve Bordeleau
    Department of Biochemistry, McGill University, Montreal, Quebec, Canada
    J Clin Invest 118:2651-60. 2008
    ..These results establish that targeting translation initiation can restore drug sensitivity in vivo and provide an approach to modulating chemosensitivity...
  88. ncbi Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics
    Maria Varela
    Liver Unit, IMDM, Barcelona Clinic Liver Cancer BCLC Group, Hospital Clinic, CIBER HEPAD, University of Barcelona, Institut d Investigacions Biomediques August Pi i Sunyer, IDIBAPS, Barcelona, Spain
    J Hepatol 46:474-81. 2007
    ..This study assesses the safety, pharmacokinetics and efficacy of transarterial chemoembolization using drug eluting beads (DEB), an embolizing device that slowly releases chemotherapy to decrease systemic toxicity...
  89. ncbi Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup
    Ian J Lewis
    Paediatric Oncology and Haematology, St James University Hospital, Leeds, UK
    J Natl Cancer Inst 99:112-28. 2007
    Previous randomized controlled trials that used the two-drug chemotherapy regimen of cisplatin and doxorubicin as the conventional arm showed no evidence of benefit from an increase in the number of agents or the length of treatment...
  90. ncbi Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene
    Xianrang Song
    Institute of Biochemistry and Molecular Biology, School of Medicine, Shandong University, Jinan, China
    Cancer Chemother Pharmacol 58:776-84. 2006
    ..We hypothesized that disruption of HIF pathway through lentiviral vector-mediated HIF-1alpha RNA interference (RNAi) could reverse the hypoxia-induced resistance to chemotherapy...
  91. ncbi pH-Responsive copolymer assemblies for controlled release of doxorubicin
    Elizabeth R Gillies
    Center for New Directions in Organic Synthesis, Department of Chemistry, University of California, Berkeley, California 94720 1460, USA
    Bioconjug Chem 16:361-8. 2005
    ..The anticancer drug doxorubicin (DOX) was encapsulated in these pH-sensitive micelles, and the acetal hydrolysis rates and DOX release rates ..
  92. pmc Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study
    Johannes Lammer
    Cardiovascular and Interventional Radiology, Medical University Vienna, Vienna, Austria
    Cardiovasc Intervent Radiol 33:41-52. 2010
    ..A widely accepted TACE regimen includes administration of doxorubicin-oil emulsion followed by gelatine sponge-conventional TACE...
  93. ncbi Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models
    Alberto Gabizon
    Experimental Oncology Laboratory, Shaare Zedek Medical Center, 11 Shmuel Bayit Street, 7th Floor, PO Box 3235, Jerusalem 91031, Israel
    Cancer Chemother Pharmacol 66:43-52. 2010
    ..Targeting liposomes to the FR has been proposed as a way to enhance the effects of liposome-based chemotherapy...
  94. ncbi Micellar carriers based on block copolymers of poly(epsilon-caprolactone) and poly(ethylene glycol) for doxorubicin delivery
    Xintao Shuai
    Department of Biomedical Engineering, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106, USA
    J Control Release 98:415-26. 2004
    ..amphiphilic block copolymers self-assembled into nanoscopic micelles and their hydrophobic cores encapsulated doxorubicin (DOX) in aqueous solutions. The micelle diameter increased from 22.9 to 104...
  95. ncbi Efficacy of interleukin-13 receptor-targeted liposomal doxorubicin in the intracranial brain tumor model
    Achuthamangalam B Madhankumar
    Department of Neurosurgery H110, G M Leader Family Laboratory, Penn State University, College of Medicine, M S Hershey Medical Center, 500 University Drive, Hershey, PA 17033 0850, USA
    Mol Cancer Ther 8:648-54. 2009
    ..Mice receiving weekly i.p. injections of 15 mg/kg of doxorubicin encapsulated in IL-13-conjugated liposomes had a 5-fold reduction in the intracranial tumor volume over 6 weeks ..
  96. pmc Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity
    Anne Aries
    Laboratory of Cardiac Growth and Differentiation, Institut de Recherches Cliniques de Montreal, Montreal, QC, Canada H2W 1R7
    Proc Natl Acad Sci U S A 101:6975-80. 2004
    ..An early event in the cardiotoxic effect of the antitumor drug doxorubicin is GATA-4 depletion, which in turn causes cardiomyocyte apoptosis...
  97. pmc Design and evaluation of doxorubicin-containing microbubbles for ultrasound-triggered doxorubicin delivery: cytotoxicity and mechanisms involved
    Ine Lentacker
    Laboratory of General Biochemistry and Physical Pharmacy, Department of Pharmaceutics, Ghent University, Ghent, Belgium
    Mol Ther 18:101-8. 2010
    ..In this article, we tried to improve the cytotoxicity of doxorubicin (DOX)-containing liposomes by preparing DOX-liposome-containing microbubbles for drug delivery with therapeutic ..
  98. pmc MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy
    Kensuke Kojima
    Section of Molecular Hematology and Therapy, Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 448, Houston, TX 77030, USA
    Blood 106:3150-9. 2005
    ..MDM2 inhibition synergistically enhanced cytotoxicity of cytosine arabinoside and doxorubicin in AML blasts but not in normal hematopoietic progenitor cells...
  99. pmc Transcription factor GATA4 inhibits doxorubicin-induced autophagy and cardiomyocyte death
    Satoru Kobayashi
    Cardiovascular Health Research Center, Sanford Research, University of South Dakota, Sioux Falls, South Dakota 57105, USA
    J Biol Chem 285:793-804. 2010
    b>Doxorubicin (DOX) is a potent anti-tumor drug known to cause heart failure. The transcription factor GATA4 antagonizes DOX-induced cardiotoxicity. However, the protective mechanism remains obscure...
  100. ncbi Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection
    P Laverman
    Department of Nuclear Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands
    J Pharmacol Exp Ther 298:607-12. 2001
    ..we describe the effects of PEG-coating, the circulation time, the lipid dose, and the presence of encapsulated doxorubicin on the pharmacokinetics upon repeated injection in rats...
  101. ncbi Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody
    Anatoly N Lukyanov
    Department of Pharmaceutical Sciences, Bouve College of Health Sciences, Northeastern University, Mugar Bldg 312, 360 Huntington Aveneu, Boston, MA 02115, USA
    J Control Release 100:135-44. 2004
    Commercially available doxorubicin-loaded long-circulating liposomes (Doxil, Alza Pharmaceuticals) were modified with the monoclonal nucleosome (NS)-specific 2C5 antibody (mAb 2C5) that recognizes a broad variety of tumors via the tumor ..

Research Grants75

  1. Bioassay for Breast Cancer Prevention
    JoEllen Welsh; Fiscal Year: 2010
    ..validate a bioassay using mammary gland in organ culture exposed to genotoxic agents (we will use radiation and doxorubicin, but this assay could be adapted for other genotoxic agents of interest)...
  2. Prolactin as a Growth Factor in Breast Cancer
    Nira Ben-Jonathan; Fiscal Year: 2013
    ..PRL) serves as a survival factor which antagonizes the cytotoxicity of the DNA-damaging agents cisplatin and doxorubicin, and the microtubule disrupting agent taxol...
  3. SFRP2 and NFAT are therapeutic targets in angiosarcoma
    NANCY K DEMORE; Fiscal Year: 2013
    ..For unresectable angiosarcoma, doxorubicin based regimens yield progression-free survival of 5 months, and paclitaxel achieves a progression-free survival ..
  4. COMBINATORIAL-DESIGNED NANO-PLATFORMS TO OVERCOME TUMOR DRUG RESISTANCE
    Zhenfeng Duan; Fiscal Year: 2013
    ..transporter and Bcl-2 and survivin anti-apoptotic genes) and cytotoxic therapeutic agents (paclitaxel and doxorubicin)...
  5. Nuclear Function of Abl in DNA Damage Response
    Jean Y J Wang; Fiscal Year: 2012
    ..gene, because we have found that activation of Abl leads to the exclusion of CD44 variable exons 4 and 5 in doxorubicin-treated cells;(2) conduct a large-scale survey of DNA damage-induced and Abl-dependent alternative splicing of ..
  6. Carboxylesterase-activated Doxazolidine-prodrug for Hepatocellular Carcinoma
    Tad H Koch; Fiscal Year: 2012
    ..The therapy is based upon doxazolidine, a formaldehyde conjugate of doxorubicin that is more than an order of magnitude more active against a variety of both sensitive and resistant (MDR ..
  7. FRET-based Biosensors to Monitor Redox in Cell Cycle Regulation
    Paul J A Kenis; Fiscal Year: 2012
    ..environment of isogenic HCT116 p53+/+ and p53-/- cells treated with the chemotherapeutic drugs fluorouracil and doxorubicin in combination with perturbations in glutathione homeostasis...
  8. Targeting Mitotic Kinases Inhibitors for Cancer Therapy
    E Premkumar Reddy; Fiscal Year: 2013
    ..the effects of combination therapy using ON1231320 and cytotoxic anti-cancer agents such as oxaliplatin, 5-fluorouracil, paclitaxel and doxorubicin to induce apoptosis and tumor regression in breast and colorectal cancer model systems.
  9. Genetics of risk of chemotherapy-induced cardiotoxicity in cancer survivors
    Peter Demant; Fiscal Year: 2013
    ..Anthracyclines (such as doxorubicin) are highly effective in treatment of hematologic malignancies (including Hodgkin and non-Hodgkin lymphoma), ..
  10. Molecular mechanism of diet induced carcinogenesis
    Samson T Jacob; Fiscal Year: 2013
    ..Determine the potential role of PTPRO in regulating invasiveness of HCC cells and their sensitization to drug (doxorubicin, 5-Fluorouracil)-induced apoptosis, and identify liver-specific substrate(s) of PTPRO by substrate-trapping ..
  11. Recombinant Polymers for Transarterial Chemoembolization of Liver Cancer
    AZADEH POURSAID; Fiscal Year: 2013
    ..drug release properties of the polymer matrix will be determined for small molecule chemotherapeutics such as doxorubicin and anti-angiogenic sorafenib and large biologics such as bevacizumab...
  12. Chemical Glycobiology on Anthracyclines
    Peng Wang; Fiscal Year: 2009
    ..Daunorubicin (DNR) and idarubicin are primarily used in leukemia and lymphoma, whereas doxorubicin (DOX) and epirubicin have broader anticancer activities against leukemia, lymphomas, and a variety of solid ..
  13. p53 Acetylation as a Mechanism in Chemoprevention by Aspirin
    JAYARAMA B GUNAJE; Fiscal Year: 2010
    ..In addition to camptothecin, all studies will be extended to include doxorubicin and cisplatin, to determine if aspirin also modulates p21 / Bax expression by these DNA damaging drugs...
  14. Trial of mesna to prevent doxorubicin-induced plasma protein oxidation and TNFa r
    Jeffrey A Moscow; Fiscal Year: 2012
    ..Since anthracyclines, such as doxorubicin, do not enter the central nervous system, the mechanism behind this debilitating sequela of therapy has ..
  15. Inflammasomes in pathogenesis of mesothelioma
    Arti Shukla; Fiscal Year: 2013
    ..Two weeks after cell injection mice will receive either saline or chemotherapeutic drugs (Doxorubicin, Cisplatin) or drugs plus Anakinra for 4-6 weeks...
  16. Alpha-1A-adrenergic agonist therapy for cardiomyopathy and heart failure
    Paul C Simpson; Fiscal Year: 2013
    ..of highly selective and potent alpha-1A agonists in mouse models of CM, including toxic CM (the cancer drug doxorubicin), ischemic CM (post-myocardial infarction), and pressure overload CM (transverse aortic constriction)...
  17. Effect of anti-S phase agents on human chromosomes
    Anindya Dutta; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Anti-S phase agents like doxorubicin, gemcitabine, cytarabine and hydroxyurea are in extensive use for the treatment of cancers and of hematological diseases such as essential thrombocytopenia, ..
  18. Application of Evolutionary Principles to Maintain Cancer Control (PQ21)
    Robert A Gatenby; Fiscal Year: 2013
    ..therapy (tamoxifen and aromatase inhibitors), (b) targeted therapy (herceptin), and (c) standard chemotherapy (doxorubicin and taxol). In preliminary experiments we will extend AT to all forms of breast cancer therapy...
  19. Improved Drug Delivery to Tumors Using Novel Tissue Perfusion Approaches
    HEIKE ELIZABETH DALDRUP-LINK; Fiscal Year: 2012
    ..abstract_text> ..
  20. Signal Transduction in the Heart after Cancer Therapy
    KATHLEEN LOUISE GABRIELSON; Fiscal Year: 2012
    ..and that it also has a central role in protecting the heart from oxidative stress (including stress induced by doxorubicin therapy)...
  21. PHARMACOGENETICS OF HUMAN CARBONYL REDUCTASES
    JAVIER GUILLERMO BLANCO; Fiscal Year: 2013
    ..the reduction of several drugs widely used in clinical practice including the anticancer anthracyclines doxorubicin and daunorubicin. The pharmacodynamics of these 2 drugs is unpredictable...
  22. Protection of Oxidant Toxicity by GSTs
    YOGESH CHANDRA AWASTHI; Fiscal Year: 2010
    ..proposed in-vitro studies using HepG2 cells transfected with Cyp2E1 and two model oxidant compounds, CCl4, and doxorubicin (DOX)...
  23. Plk1 in Chemo-resistance of Cancer
    Xiaoqi Liu; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Plk1 in chemoresistance of cancer Abstract: Paclitaxel and doxorubicin have been widely used to treat various cancers...
  24. Synthesis, Biosynthesis, and Structure of Antitumor Agents
    Thomas R Hoye; Fiscal Year: 2013
    ..of the following either is a natural product itself or is directly derived from one: actinomycin, bleomycin, doxorubicin/daunorubicin/darubici/valrubicin (from daunomycin), etoposide/teniposide (from podophyllotoxin), irinotecan/..
  25. MCJ function in mouse mammary tumor properties
    Mercedes Rincon; Fiscal Year: 2009
    ..that inhibition of MCJ expression in drug-sensitive cells induces resistance to specific drugs (paclitaxel, doxorubicin) in vitro...
  26. Synthetic Cell Surface Receptors for Anticancer Drug Delivery
    Blake Peterson; Fiscal Year: 2012
    ..peptide substrates of tumor-specific proteases will be used to link cholesterylamines to the anticancer drug doxorubicin. This drug will be selectively released when cleaved by the MMP-2 protease expressed by metastatic cancer cells...
  27. Mechanism of action of TOP2-directed anticancer drugs
    Leroy F Liu; Fiscal Year: 2012
    ..Top2-targeting drugs such as etoposide (VP-16), doxorubicin and mitoxantrone are among the most effective and widely used anticancer drugs in the clinic...
  28. Targeting the cell cycle in triple negative breast cancer
    Khandan Keyomarsi; Fiscal Year: 2013
    ..rate (RR) and biologic effects of CDK2 inhibition with roscovitine (Seliciclib) given prior to liposomal doxorubicin in patients with metastatic TNBC...
  29. Evaluation of a Novel Glutathione Reductase Inhibitor as a Model to Induce Thiol
    Teresa Seefeldt; Fiscal Year: 2010
    ..ischemia-reperfusion injury following a myocardial infarction, heart failure, diabetic cardiomyopathy, and doxorubicin-induced cardiotoxicity...
  30. Rapid release paclitaxel nanoparticles for bladder cancer intravestical therapy
    Ze Lu; Fiscal Year: 2009
    ..and clinical studies, an important lesson learned is that the efficacy of intravesical mitomycin (MMC) or doxorubicin therapy is limited by two factors, i.e...
  31. Multifunctional nanoparticles for targeting aberrant tumorigenic pathways
    Shiladitya Sengupta; Fiscal Year: 2013
    ..the mitogen activated protein kinase (MAPK) pathway, a critical oncogenic pathway, and additionally deliver doxorubicin after homing into the tumor...
  32. New Thermal Sensitive Carboplatin Liposome for Cancer
    Robert A Reed; Fiscal Year: 2010
    ..With a thermal sensitive liposomal product containing doxorubicin, (LTSL-Dox, or ThermoDox(R)) already in Phase I/II human clinical trials for recurrent chest wall, and Phase ..
  33. LPD Nanoparticles in Anti-Cancer Therapy
    Leaf Huang; Fiscal Year: 2012
    ..e., LPH, which contains heparin sulfate to deliver doxorubicin (dox), a potent anti-cancer drug, either by itself or together with EGFR siRNA...
  34. Multiscale Mathematical Modeling of Cancer Progression
    Vito Quaranta; Fiscal Year: 2013
    ..trait heterogeneity and fitness cost in the rise of breast cancer resistance to first- and second-line drugs (doxorubicin, hormone therapy and HER2 tyrosine kinase inhibitors)...
  35. Hepatic OATP Drug Transporters and Chemotherapy Disposition
    RICHARD HSINSHIN HO; Fiscal Year: 2013
    ..used chemotherapeutic agents known to be dependent on hepatic clearance, including docetaxel, vincristine and doxorubicin. Focused studies that aim to better delineate the kinetic and inhibition profiles, genetic basis for ..
  36. Mechanism of Activity of Lonidamine
    Jerry D Glickson; Fiscal Year: 2013
    ..LND, 100 mg/kg) substantially enhances the activity of melphalan and have now extended this finding to doxorubicin treatment...
  37. DNA Methyltransferase Inhibition by Intercalating Agents
    Keith D Robertson; Fiscal Year: 2010
    Anti-cancer drugs of the DNA intercalator class, which includes doxorubicin (adriamycin), are among the most effective and widely used agents in systemic cancer chemotherapy...
  38. Juvenile mouse model of delayed anthracycline cardiotoxicity
    Asa B Gustafsson; Fiscal Year: 2013
    Project Summary/Abstract While anthracyclines such as doxorubicin (DOX) are among the most effective chemotherapeutic agents and commonly used to treat pediatric cancers, they are problematic because they are associated with ..
  39. Intra-bladder MMC &suramin for nonmuscle-invading &locally advanced bladder ca
    Ze Lu; Fiscal Year: 2012
    ..The most commonly used chemotherapeutic agents for intravescial therapy are mitomycin C (MMC) and doxorubicin. Through a series of preclinical and clinical studies, our group has established that the efficacy of these ..
  40. In situ assay for DNA cleavage by topoisomerase II
    BENXIAO ZHANG; Fiscal Year: 2011
    ..Drugs that modify this activity of TOPO II, such as etoposide and doxorubicin, form a class of TOPO II inhibitors that act by triggering the generation of DNA breaks by TOPO II...
  41. Development of a CES 2-Activated Doxazolidine Prodrug for Pancreatic Cancer
    Tad H Koch; Fiscal Year: 2010
    ..The therapy is based upon doxazolidine, a formaldehyde conjugate of doxorubicin that is more than an order of magnitude more active against a variety of both sensitive and resistant (MDR ..
  42. Characterizing and Targeting CHD4 Deficiency in Endometrial Cancer
    Shiaw Yih Lin; Fiscal Year: 2013
    ..We will also combine PARP inhibitors with radiation and with doxorubicin or paclitaxel to establish optimal therapies...
  43. Neuregulin1 Alleviation of the "On-Target" Cardiotoxicity Caused by Inhibition of
    Xinhua Yan; Fiscal Year: 2013
    ..A dose-related cardiotoxicity is a major clinical barrier for using the first-line chemotherapy drug doxorubicin (DOX) in cancer patients...
  44. Elimination of residual malignancy by programmed systemic cytokine gene therapy
    Shulin Li; Fiscal Year: 2013
    ..We also found that doxorubicin, an anti-neoplasm drug, potentiates IL-12- mediated eradication of highly malignant 4T1 tumors and induces the ..
  45. Plasma Mitochondrial Peptide Assays as Biomarkers of Environmental Toxin Exposure
    Pinchas Cohen; Fiscal Year: 2013
    ..their levels in human diseases states associated with mitochondrial dysfunction and in mice subjected to acute doxorubicin exposure...
  46. Ginseng and its Constituents in Complementary Breast Cancer Therapy
    Laura Murphy; Fiscal Year: 2010
    ..In our preliminary data, we demonstrate that ginseng increases the anti-cancer efficacy of the chemotherapeutic doxorubicin on breast cancer cells in vitro and on tumor growth in vivo, and further prevents the weight loss associated ..
  47. Mechanistic insights into the cardioprotective effects of mABC1 protein
    Hossein Ardehali; Fiscal Year: 2013
    ..iron accumulation and leads to the development of cardiomyopathy, while mABC1 TG mice are resistant to doxorubicin-induced cardiotoxicity and have lower mitochondrial iron levels...
  48. Cell-Penetrating Anti-DNA Antibody for Radiosensitization and Cancer Therapy
    Peter M Glazer; Fiscal Year: 2013
    ..In preliminary work, 3E10 was found to greatly potentiate the effects of low-dose doxorubicin in BRCA2-deficient cells but not in BRCA2-proficient cells, providing a large therapeutic gain...
  49. FGFR2 as a Therapeutic Target in Endometrial Cancer.
    Matthew A Powell; Fiscal Year: 2011
    ..Cytotoxic agents (doxorubicin, cisplatin, paclitaxel) have had limited success in the treatment of aggressive endometrial cancer...
  50. Screening of inhibitors for human 5-prime-tyrosyl DNA phosphodiesterase (hTDP2)
    Sanjay Adhikari; Fiscal Year: 2013
    ..Future Plan and long term goal: We will test the small molecule inhibitors as an adjuvant to etoposide or doxorubicin treatment in different cancer cell lines and orthotopic model of lung cancer.
  51. Engineered intelligent micelle for tumor pH targeting
    You Han Bae; Fiscal Year: 2013
    ..Our results demonstrated that 1) doxorubicin (DOX) loaded micelles were equally cytotoxic to sensitive MCF-7 (breast) and A2780 (ovarian) cancer cells and ..
  52. Enabling high dose regional chemotherapy while minimizing systemic toxicity
    Shaker A Mousa; Fiscal Year: 2010
    ..is to develop a filtration system that maximizes the removal (>90%) of chemotherapeutic agents, such as doxorubicin, from blood while minimizing adverse effects of filtration on blood chemistry and hematological parameters...
  53. A Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL
    MICHAEL JAMES BURKE; Fiscal Year: 2012
    ..Chemotherapy with vincristine, prednisone, PEG-asparaginase and doxorubicin will begin on day 8. Decitabine and vorinostat will be restarted on day 15 and 17 respectively through day 21...
  54. Effects of chemotherapeutic agents on learning and memory in mice
    ELLEN ANN WALKER; Fiscal Year: 2013
    ..Specifically, we will treat male and female mice with multiple doses of cyclophosphamide, doxorubicin, 5-fluorouracil, methotrexate, tamoxifen, and docetaxel at various time points to measure effects on ..
  55. Novel therapy for cardiotoxicity of cancer drugs
    Paul C Simpson; Fiscal Year: 2013
    ..Cardiotoxicity of anthracyclines, for example doxorubicin (Adriamycin), is well recognized, and cardiotoxicity is an emerging problem with novel cancer therapies, such ..
  56. Effects of Antioxidant Supplementation during Breast Cancer Adjuvant Therapy
    Heather Greenlee; Fiscal Year: 2013
    ..For example, coenzyme Q10 (C0QIO), a lipid soluble antioxidant, has been hypothesized to decrease doxorubicin-induced cardiotoxicity...
  57. Combination chemo-siRNA gene therapy of nonmuscle-invading bladder cancer
    Ze Lu; Fiscal Year: 2012
    ..The most commonly used chemotherapeutic agents for intravescial therapy are mitomycin C (MMC) and doxorubicin. Through a series of preclinical and clinical studies, our group has established that their efficacy is limited ..
  58. The role of mitochondria in skeletal muscle fatigue caused by cancer chemotherapy
    LAURA ANN ASHLEY GILLIAM; Fiscal Year: 2013
    ..In my dissertation research I found that healthy mice given doxorubicin, a chemotherapy drug, had decreased muscle force and an accelerated rate of fatigue...
  59. Novel Polymeric nanoparticles for drug delivery applications
    Anthony J McGoron; Fiscal Year: 2013
    ..PGMD Nps simultaneously loaded with imaging agent and chemotherapy drugs (doxorubicin, cisplatin, or paclitaxel) will deliver the drugs to the tumor site with a greater payload than existing drug ..
  60. Drug Resistance in Cancer Therapy
    VINOD D LABHASETWAR; Fiscal Year: 2013
    ..This was evident from a 13-fold enhancement in efficacy of doxorubicin and 25-fold of paclitaxel (PTX) in a resistant cell line and sustained tumor inhibition based on a single-dose ..
  61. Tumor Targeted Corroles for Detection and Intervention
    Lali K Medina-Kauwe; Fiscal Year: 2013
    ..at nearly 300x less dosage in comparison to direct intratumoral delivery of the chemotherapy agent, doxorubicin. HER2+ cancer has served as a model system for testing new targeted therapeutics in our lab...
  62. SUBSTANCE P-MEDIATED CARDIOVASCULAR INFLAMMATION
    William Weglicki; Fiscal Year: 2009
    ..3. Determine if cardiac dysfunction/failure mediated by the anticancer drug, doxorubicin (DOX), is enhanced by SP-mediated inflammation and associated endotoxemia during MgD...
  63. Inhibition of glutathione reductase and ovarian cancer drug resistance reversal
    Xiangming Guan; Fiscal Year: 2006
    ..drug resistance to the first line and second line ovarian cancer chemotherapeutic agents such as cisplatin and doxorubicin. We have obtained preliminary data with a GSH-mediated drug resistant human ovarian cancer cell line (OVCAR-3) ..
  64. MODULATION OF MULTIDRUG RESISTANCE BY CYCLOSPORIN A
    Charles Erlichman; Fiscal Year: 1992
    ..resistance (MDR) phenotype may be an important determinant of both experimental and clinical resistance to doxorubicin and other anthracyclines, to vinca alkaloids, and to etoposide...
  65. NATIONAL WILMS TUMOR STUDY -5
    Daniel Green; Fiscal Year: 2003
    ..with only nephrectomy, radiation therapy and three-drug chemotherapy with vincrintine, dactinomycin and doxorubicin results in long-term relapse- free survival of 85% of patients with stage III and IV, favorable histology WT...
  66. PHARMACODYNAMICS OF AGENTS FOR BLADDER CANCER THERAPY
    JESSIE AU; Fiscal Year: 2003
    ..We propose to establish, for doxorubicin and thiotepa, (a) drug concentration-time profiles in blood and urine, (b) extent and rate of systemic ..
  67. DOXORUBICIN BIOSYNTHESIS AND RESISTANCE
    CHARLES SIH; Fiscal Year: 2000
    DESCRIPTION: This application proposes to investigate the genetic and biochemical regulation of doxorubicin (DXR) production in Streptomyces peucetius. DXR is an important cancer chemotherapy drug produced commercially by fermentation...
  68. GLUTATHIONE BIOSYSTHESIS AND DRUG RESISTANCE
    R Mulcahy; Fiscal Year: 1999
    ..changes associated with inmate or acquired resistance to alkylating agents, analogs of cisplatinum and doxorubicin. Despite a long-standing association between elevated GSH and drug resistance, details of the molecular ..
  69. Poly (amino acid) as an Integrin Targeted Drug Carrier
    Xiaoling Li; Fiscal Year: 2005
    ..1) to synthesize novel random terpolymers containing leucine, aspartic acid, and valine and covalently link doxorubicin to this integrin targeted drug carrier, 2) to verify the target specificity of the carrier to malignant ..
  70. PHARMACODYNAMIC CORRELATES IN ADVANCED GASTRIC CANCER
    Charles Coltman; Fiscal Year: 1992
    ..Recent reports suggest that FAMTX chemotherapy (a combination of 5-Fluorouracil, doxorubicin, and methotrexate with leucovorin rescue) has a superior response rate and associated median survival than FAM ..
  71. Role of Proteinase-3 in Apoptosis and Drug Resistance
    AHMAD SAFA; Fiscal Year: 2007
    ..fin reactive oxygen species (ROS) generation and drug-induced apoptosis, and increased cellular resistance to doxorubicin (DOX) or daunorubicin (DNR)...
  72. Nanoparticle targeting of cathepsin-L inhibitor and doxorubicin in breast cancer
    Shaker Mousa; Fiscal Year: 2007
    ..ability of cathepsin L inhibitor to reverse drug resistance in vivo utilizing nude mice bearing xenografts of doxorubicin resistant neuroblastoma cell line SKN-SH/R drug resistant tumors...
  73. A nanoparticle prognosticator of chemotherapy outcomes
    Russell Lebovitz; Fiscal Year: 2009
    ..significant discovery it was shown that NCTX can predict the outcome of chemotherapy using Stealth Liposomal Doxorubicin (SLD). NCTX consists of a clinically used Iodinated contrast agent encapsulated in a Pegylated liposome...
  74. NEW DRUGS FOR RESISTANT DISEASE FROM CI/MS STUDIES
    VERONICA BIERBAUM; Fiscal Year: 2000
    ..Although adriamycin (doxorubicin) and other anthracycline drugs are valuable chemotherapeutic agents, a major problem associated with their use ..
  75. CHEMOMYECTOMY FOR EYELID SPASMS
    Linda McLoon; Fiscal Year: 1999
    ..We have developed a novel permanent, non-surgical treatment for these diseases, doxorubicin chemomyectomy...